Following a mandate by the Commission in 2016 to undertake a re-evaluation of BPA, to take account of the results of new studies and scientific data to address remaining uncertainties, including the output from a two-year chronic study from the United States’ National Toxicology Program, the Authority published an updated opinion on BPA in 2023 [EFSA Journal 2023; 21(4):6857.]. In this opinion, the Authority concluded that BPA exerts a number of adverse effects, including on the immune system, which it considered the most sensitive to effects from BPA. On that basis, the Authority established a tolerable daily intake (TDI) of 0,2 nanograms per kilogram (ng/kg) bodyweight, which is 20000 times lower than the temporary TDI of 4 micrograms per kilogram (μg/kg) (or 4000 ng/kg) bodyweight it established in its 2015 opinion. The Authority noted that a dose range similar to that which led to effects on the immune system also caused adverse metabolic effects as well as adverse effects on the reproductive and developmental systems. Comparison of the TDI of 0,2 ng/kg bodyweight with the dietary exposure estimates from the Authority’s 2015 opinion indicates that the exposure for all age groups exceeds the TDI by two to three orders of magnitude. The Authority therefore concluded that there is a health concern from dietary BPA exposure for all population groups.
Recital 3, Regulation (EU) 2024/3190
In forcesince 19 Dec 2024